Overview

Basic information

Litigation

Active legal matters

Material Events

8-K disclosures

SEC Filings

Key regulatory docs

Insider Transactions

Ownership changes

Overview

Basic information

Litigation

Active legal matters

Material Events

8-K disclosures

SEC Filings

Key regulatory docs

Insider Transactions

Ownership changes

Apellis Pharmaceuticals, Inc. (APLS) Class Action Lawsuit (August 2023)

In Litigation

25-1383 • August 2, 2023

Class Period Start

January 28, 2021

Class Period End

July 28, 2023

PSLRA Deadline

October 2, 2023

Case Allegations

10b5

Statutes of Repose

Jan 28, 2024

Country

United States

Court

Federal Court

Docket History

Apr 22, 2025

On Appeal

Mar 17, 2025

Motion to Dismiss Granted

The court has granted the defendants' request to dismiss the lawsuit. Depending on the court's decision, the plaintiffs may be allowed to file an updated complaint or pursue an appeal.

Jun 12, 2024

Motion to Dismiss

After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.

Feb 8, 2024

First Amended Complaint

A new complaint has been filed on behalf of certain investors in Apellis Pharmaceuticals, Inc.. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.

Oct 23, 2023

Appointment of Lead Plaintiff

The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.

Aug 2, 2023

First Filed Complaint

A securities fraud class action complaint has been filed on behalf of certain investors in Apellis Pharmaceuticals, Inc..

TOP